BRAS Symposium 2011 - 27 Octobre 2011 - Sheraton Rogier

08.30 REGISTRATION & COFFEE

09.00 Welcome Address
Pieter De Pourcq

09.15 Setting the scene

Present: where are we now ?

Presentations by NIHDI

09.30 Main structural changes at NIHDI to come to the new assessment procedure: from TRFS/ CTSP to CTG/CRM

09.50 Assessment of the applications

10.10 Re-evaluation of the reimbursement decisions

10.30 COFFEE BREAK

11.00 Orphan drug reimbursement:
evaluation and evolution

11.20 Health economics and budget impact

11.40 Budget control

12.00 Agreement with the Institute (NIHDI)

12.30 Panel discussion
Moderated by Johan Ral

13.00 LUNCH

Future: Quo Vadis ?

14.00 Industry: business models for the development of new innovative, biosimilar and generic drugs

Presentation by a representative of a company
Marc Tomas

14.20 Presentation by a representative of pharma.be
Herman Van Eeckhout

14.40 Presentation by a representative of FeBelGen
Johan Eykens

15.00 The Belgian Health Care Knowledge Centre (KCE) 
Report on CRM: findings and recommendations
Irina Cleemput

15.30 COFFEE BREAK

16.00 Reimbursement decisions: Quo vadis ?
Internal assessment: results and implications
Bruno Flamion - Ri De Ridder

16.45 Panel discussion
Moderated by Johan Ral

17.00 Wrap up
Jo De Cock

17.15 Closing remarks
Pieter De Pourcq

17.30 COCKTAIL

Accessible to BRAS members and non members.